Clinical Trial Update: CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing CAPOXIRI+Bevacizumab versus FOLFOXIRI+Bevacizumab for metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CAPOXIRI+Bevacizumab
• FOLFOXIRI + Bevacizumab

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN